journal article·2020-11-25Open access

Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles

Yin Liu, Jiao Wang, Jian Zhang, Sandra Marbach, Wei Xu, Lin Zhu

ACS Applied Materials & Interfaces· Volume 12· Issue 47

Abstract

Tumor-associated macrophages (TAMs), a major player in the tumor microenvironment, were recently recognized as a potential therapeutic target. To date, very few anticancer drugs or drug-delivery systems were designed to target the TAMs. Inspired by the "eat me" signal, phosphatidylserine (PS), mediated phagocytic clearance of apoptotic bodies, in this study, the matrix metalloproteinase 2 (MMP2)-sensitive PS-modified nanoparticles were developed. In the design, the PS is externalized to the nanoparticles' surface only when the nanoparticles reach the MMP2-overexpressing tumor site, allowing for the TAM-specific phagocytosis. The nanoparticles' excellent macrophage/TAM selectivity was observed in various biological models, including various cell lines, coculture cells, coculture cell spheroids, zebrafish, and tumor-bearing mice. The nanoparticles' TAM specificity remarkably enhanced the TAM depletion capability of the loaded model drug, dasatinib, resulting in the improved anticancer activity. The MMP2-sensitive apoptotic body-mimicking nanoparticles might be a promising delivery tool for TAM-centered cancer diagnoses and treatments.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immune cells in cancer · Nanoparticle-Based Drug Delivery · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University College Station, Kingsville 78363, Texas, United States

Department of Life Sciences, College of Science and Engineering, Texas A&M University, Corpus Christi 78412, Texas, United States

Funding

National Cancer Institute · Texas A and M University

References (62)

Show source-provided references
1. 10.1038/250667a010.1038/250667a0 ↗
2. 10.1016/j.immuni.2014.06.01010.1016/j.immuni.2014.06.010 ↗
3. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
4. 10.1038/sj.bjc.660324010.1038/sj.bjc.6603240 ↗
5. 10.1158/0008-5472.can-14-339410.1158/0008-5472.can-14-3394 ↗
6. 10.1016/j.ccr.2010.11.00910.1016/j.ccr.2010.11.009 ↗
7. 10.1038/nrc74510.1038/nrc745 ↗
8. 10.1016/j.cell.2010.03.01510.1016/j.cell.2010.03.015 ↗
9. 10.1016/s0092-8674(00)81235-010.1016/s0092-8674(00)81235-0 ↗
10. 10.1016/j.bbamcr.2009.09.01710.1016/j.bbamcr.2009.09.017 ↗
11. Zucker S. · Cancer Epidemiol., Biomarkers Prev. · 1992 · 1 · 475
12. 10.1016/s0959-8049(03)00427-110.1016/s0959-8049(03)00427-1 ↗
13. 10.1002/ijc.2198910.1002/ijc.21989 ↗
14. 10.3892/ijo.17.4.67310.3892/ijo.17.4.673 ↗
15. Schmalfeldt B. · Clin. Cancer Res. · 2001 · 7 · 2396
16. 10.1016/j.prp.2011.09.01010.1016/j.prp.2011.09.010 ↗
17. 10.1007/s12013-013-9701-x10.1007/s12013-013-9701-x ↗
18. 10.1038/nrd439010.1038/nrd4390 ↗
19. 10.1016/j.tips.2018.06.00310.1016/j.tips.2018.06.003 ↗
20. 10.1083/jcb.20010808010.1083/jcb.200108080 ↗
21. 10.1016/j.jconrel.2014.03.04310.1016/j.jconrel.2014.03.043 ↗
22. 10.1038/sj.bjp.070730210.1038/sj.bjp.0707302 ↗
23. 10.4049/jimmunol.170.9.484010.4049/jimmunol.170.9.4840 ↗
24. 10.1194/jlr.m800405-jlr20010.1194/jlr.m800405-jlr200 ↗
25. 10.1016/j.freeradbiomed.2006.12.00310.1016/j.freeradbiomed.2006.12.003 ↗
26. 10.1021/acsami.6b0306410.1021/acsami.6b03064 ↗
27. 10.1021/nn300524f10.1021/nn300524f ↗
28. 10.1016/j.nano.2019.03.01210.1016/j.nano.2019.03.012 ↗
29. 10.1021/acsami.7b0951110.1021/acsami.7b09511 ↗
30. 10.1166/jbn.2016.224910.1166/jbn.2016.2249 ↗
31. 10.1016/j.jconrel.2015.06.02410.1016/j.jconrel.2015.06.024 ↗
32. 10.1109/tps.2006.87650110.1109/tps.2006.876501 ↗
33. 10.1016/j.biomaterials.2011.01.02110.1016/j.biomaterials.2011.01.021 ↗
34. 10.1016/0022-1759(95)00072-i10.1016/0022-1759(95)00072-i ↗
35. 10.1038/leu.2008.23710.1038/leu.2008.237 ↗
36. 10.18632/oncotarget.1810310.18632/oncotarget.18103 ↗
37. 10.4049/jimmunol.173.11.697310.4049/jimmunol.173.11.6973 ↗
38. 10.1016/j.ymthe.2005.03.03810.1016/j.ymthe.2005.03.038 ↗
39. Ivanov A. I. · 2008 · 1510.1007/978-1-59745-178-9_2 ↗
40. 10.1074/jbc.270.29.1725010.1074/jbc.270.29.17250 ↗
41. 10.1016/j.cub.2006.09.03210.1016/j.cub.2006.09.032 ↗
42. Acton S. · J. Biol. Chem. · 1993 · 268 · 353010.1016/S0021-9258(18)53727-3 ↗
43. 10.1016/j.nantod.2015.06.00610.1016/j.nantod.2015.06.006 ↗
44. 10.1016/j.canlet.2004.02.00710.1016/j.canlet.2004.02.007 ↗
45. 10.1039/c9cc01344j10.1039/c9cc01344j ↗
46. 10.1172/jci8725210.1172/jci87252 ↗
47. Hauptmann S. · Am. J. Pathol. · 1993 · 143 · 1406
48. 10.1038/nrd160610.1038/nrd1606 ↗
49. 10.1038/bjp.2008.24910.1038/bjp.2008.249 ↗
50. 10.1021/nn501912610.1021/nn5019126 ↗
51. 10.1002/0471142735.im2002s3910.1002/0471142735.im2002s39 ↗
52. 10.1172/jci2764810.1172/jci27648 ↗
53. 10.1016/j.celrep.2016.04.08410.1016/j.celrep.2016.04.084 ↗
54. 10.1073/pnas.130498711010.1073/pnas.1304987110 ↗
55. 10.1016/j.biomaterials.2015.07.02710.1016/j.biomaterials.2015.07.027 ↗
56. 10.1158/1078-0432.ccr-11-107110.1158/1078-0432.ccr-11-1071 ↗
57. 10.1158/2326-6066.cir-16-0061-t10.1158/2326-6066.cir-16-0061-t ↗
58. 10.1182/blood-2012-02-40716310.1182/blood-2012-02-407163 ↗
59. 10.1021/acsami.7b1223310.1021/acsami.7b12233 ↗
60. 10.1021/acsami.7b1121910.1021/acsami.7b11219 ↗
61. Westerfield M. · 2007
62. 10.1002/0471142735.im2002s3910.1002/0471142735.im2002s39 ↗